Quest Diagnostics Incorporated Q4 FY2025 earnings call

• Jim Davis noted that in 2025, the company generated double-digit growth in revenues and earnings per share, expanded clinical innovation, formed strategic collaborations, and advanced its position in the wellness industry. He commented on PAMA legislation, highlighting the one-year delay but emphasizing the need for structural fixes via the RESULTS Act.
• In the physician channel, there was high single-digit organic revenue growth in the fourth quarter due to broad-based demand for clinical solutions and geographic expansion. In the hospital channel, revenues grew low single digits with Collaborative Lab Solutions driving growth. The consumer channel leveraged diagnostics expertise and technology, with questhealth.com expanding to offer over 150 tests and partnerships with wellness companies.
• Clinical innovations highlighted included autoimmune testing, brain health tests for Alzheimer’s, and oncology tests like Haystack MRD and flow MRD. Operational excellence was achieved through the INFIGURATE program, which delivered 3% annual cost savings and productivity improvements, along with AI and automation initiatives to enhance customer and employee experiences.

In the fourth quarter, consolidated revenues were $2.81 billion, up 7.1% versus the prior year. Consolidated organic revenues grew by 6.4%. Revenues for Diagnostic Information Services were up 7.3% compared to the prior year, reflecting organic growth in physician, hospital, and consumer channels as well as recent acquisitions. Total volume, measured by the number of requisitions, increased 8.5% versus 2024, with organic volume up 7.9%. Total revenue per requisition was down 0.1% versus the prior year. Excluding Corewell Health and Fresenius Medical Care, organic volume growth accelerated to 4.1% in the fourth quarter, while revenue per requisition growth remained solid at approximately 3%.

• 2026 revenues are expected to be between $11.7 billion and $11.82 billion, representing a growth rate of 6% to 7.1%. Reported EPS is expected to be in the range of $9.45 to $9.65 and adjusted EPS in the range of $10.50 to $10.70. Cash from operations is expected to be approximately $1.75 billion, and capital expenditures are expected to be approximately $550 million.
• Guidance considers approximately 6%-7.1% revenue growth (excluding M&A contribution), weather impact in January 2026, no PAMA impact in 2026, ~$0.25 EPS dilution from Project Nova, and CoLab with Corewell adding ~$250 million organic revenue at low single-digit margins in 2026.

• PAMA structural flaws: Reliance on an estimated 10,000 plus labs to self-report data for payment rate setting, which has led to inaccurate market-based rates in the past. The need for the RESULTS Act to provide a better data collection solution.
• Weather impact: Severe weather in January 2026 created a greater headwind than the same period in 2025, though it is factored into the full-year guidance.

Q: Luke Sergott asks about 2026 growth drivers, including consumer piece, new tests, and reimbursement A: Jim Davis mentions strong organic growth from Alzheimer’s tests, autoimmune testing, consumer segment growth via questhealth.com and partnerships, and network reentry with Elevance and Sentara Q: Luke Sergott follows up on 1Q weather impact and pacing A: Jim Davis and Sam Samad discuss weather impact in January and recovery potential, noting seasonality is expected to be in line with last year Q: Patrick Donnelly asks about margins and moving pieces in 2026 A: Sam Samad talks about operating margin expectations, Corewell's impact on margins, organic growth, price impact, Haystack's effect, and Project Nova's dilution Q: Michael Cherny asks about competitive environment and share gain A: Jim Davis highlights share gains from network reentry, national coverage, and capitalizing on health system priorities away from lab testing Q: Kevin Caliendo asks about HIX impact and organic volumes ex-Fresenius and Corewell A: Sam Samad comments on HIX modeling and volume growth ex-Fresenius and Corewell being over 4%